A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

AstraZeneca AB0 个研究点目标入组 40,000 人开始时间: 2020年11月9日最近更新: 2021年3月8日

研究概览

暂无简介。

•- Increased risk of SARS-CoV-2 infection, Defined as adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19, based on available risk assessment contemporaneous to enrollment (believed to be at risk/exposure)
•- Medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30000
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10000

•- Any confirmed or suspected immunosuppressive or immunodeficient state, including asplenia
•- Any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data
•- Receipt of, or planned receipt of investigational products indicated for the treatment or prevention of SARS-CoV-2 or COVID-19 Note: For participants who become hospitalized with COVID-19, receipt of licensed treatment options and/orparticipation in investigational treatment studies is permitted

发起方